Team of engineers seeking to improve the treatment of chronic wounds
Annually in the United States, over 6 million individuals suffer from chronic wounds. This creates a net annual health care cost of over $20 billion. The large cost and time it takes to heal these wounds with current methods lead many to be suffer from unintended secondary infections and hospital fees that not all can afford.
Why We Care
Expedient healing is highly desirable to minimize pain, discomfort, potential infection, and compromised daily activities. BubMed believes that is both our goal and that of the doctors to provide the most effective and cost efficient treatments to their patients.
BubMed's goal is to create a lifetime system for hospitals to employ to heal patients with open wounds. The initial investment for our wound healing system will be a negligible cost compared to the benefits provided to the patients. It is our goal to work with the hospitals to create a system that they can offer as an affordable treatment to those that need it.
To combine the science of micro-nanobubbles with that of current wound healing technologies to further advance the way wound treatment is performed. With BubMed technology, doctors will be able to nearly cut in half the healing time and costs needed to treat patients with chronic wounds.
BubMed's system is derived from intellectual property from the University of California, Irvine's Department of Biomedical Engineering. It combines Micro-NanoBubble technology along with Negative Pressure Wound Therapy to expedite the wound healing process. Our system seamlessly generates pressurized solutions to deliver and collect from the wound site.
Micro-nanobubbles (MNBs) improve wound debridement through providing increased oxygenation to the skin cells. The BUbMed system can be divided into three main subsystems: the MNB generation system, the solution delivery system, and the waste collection system. The delivery system for our current prototype is a commercially available spray-jet nozzle utilized by the Smith and Nephew VersaJet II Hydrosurgery System.
As a non-invasive device, the BubMed system classifies as a FDA Class II Special Controls device. This requires that only a 510(k) premarket notification be submitted along with clinical data to satisfy all regulatory requirements before commercialization can be achieved. The clinical trials needed are projected to be completed within the next 15 months.
The BubMed system will be an initial investment purchase from hospitals. The initial revenue is projected to be $1500 per system in the first year following commercialization, and reach $3000 per system by its 3rd year. The BubMed system also has a consumable component will create recurring revenue from its clients. The hospitals will need to replace nozzle tips per use to maintain sterility and cross-contamination standards. The projected revenue will be $0.20 per tip replacement.
Advised by Dr. Michael Klopfer of the CalPlug Research Group at University of California, Irvine.
Lets get in touch. Send us a message: